louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03291860: Antimullerian Hormone as an Indicator for Ovarian Response
Official title: Antimullerian Hormone as an Indicator fo Ovarian Response in Women Receiving Long GnRH Agonist Protocol in Intracytoplasmic Sperm Injection Cycles
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility, Female
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2017-09-25
Enrollment: 66
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Sixty six women undergoing ICSI were enrolled in and a written informed consent was obtained from each participant

Brief summary: Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.

Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.


Eligibility criteria: Inclusion Criteria:

1. Age:20-40 years old
2. BMI:20-40kg/m
3. Normal baseline hormonal profile (on the 2nd day of the cycle)

   * FSH: 2.5-10.2mlU/ml
   * LH:1.9-12.5mlU/ml
   * Estradiol (E2): \<50pg/ml
4. No Endometriosis by laparoscopy
5. No prior ovarian surgery; overectomy, ovariectomy or oophrectomy
6. Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy

Exclusion Criteria:

* 1. Age: \<20 or \>40 years old 2. BMI: \<20 or \>40kg/m 3. Female subjects with any contraindication for pregnancy. 4. Female subjects with history of tumors of the hypothalamus \& pituitary gland.

  5. Female subjects with history of ovarian, uterine or mammary cancer. 6. Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.

  7. Abnormal baseline hormonal profile 8. Endometriosis by laparoscopy 9. Previous ovarian surgery; overectomy, ovariectomy or oophrectomy 10. Female subjects with abnormal gynecological bleeding of unknown etiology

Primary outcomes:
measure: Difference between AMH levels between good and poor responders in young patients receiving long GnRH agonist protocol for ICSI.
timeFrame: 1 month (1 cycle)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06703060: A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation Among Black Women
Official title: Trauma-Informed HIV Prevention for Black Women in Baltimore
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: HIV Prevention
PrEP
Women
Intimate Partner Violence (IPV)
Lead sponsor: Johns Hopkins Bloomberg School of Public Health
Sponsor class: OTHER
Collaborators: name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2024-11-25
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: U.S. epidemiological data indicates that Black women are a high-risk HIV disparity group, yet initiation of novel prevention strategies like pre-exposure prophylaxis (PrEP) among this group is stagnant. Socio-structural challenges like intimate partner violence and gendered racism can constrain PrEP access among Black women, but few implementation studies have mitigated these challenges to improve PrEP initiation. The proposed research aims to implement and assess the effectiveness, implementation, and sustainability of a multilevel intervention to increase PrEP initiation among Black women with and without intimate partner violence in Baltimore.


Eligibility criteria: Inclusion Criteria:

* self-identified Black cisgender woman;
* self-reported HIV-negative status, and
* ≥18 years.
* reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner,
* have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and
* never taken PrEP

Exclusion Criteria:

* non-English speaking and
* currently living with HIV

Primary outcomes:
measure: PrEP initiation
timeFrame: Post baseline up to 6 months
Secondary outcomes:
measure: PrEP adherence
timeFrame: 2-months post-randomization, 4-months post-randomization, and 6-months post-randomization
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Bloomberg School of Public Health
state: Maryland
Study officials:
affiliation: Johns Hopkins Bloomberg School of Public Health
name: Tiara C. Willie, PhD, MA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03004560: Psychology of Minimally Invasive Surgical Scars
Official title: Psychology of Minimally Invasive Surgical Scars
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obesity
Keywords: Bariatric
standard laparoscopic surgery
minimally invasive
scars
psychology
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Teleflex
First posted: 2016-12-29
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to examine the psychological and psychosocial impact of surgical scars after minimally invasive surgery (MIS). 100 adult patients who are about to undergo bariatric procedures through the Duke Metabolic \& Weight Loss Surgery program will be enrolled in this study. 50 patients will be randomly assigned to standard laparoscopic surgery and 50 will be assigned to the percutaneous group. All patients will complete pre-operative psychometric testing to establish a baseline body-image score as well as a patient's initial subjective perceptions around surgery and surgical scars. Follow-up visits will be done at standard of care timepoints - 3 weeks, 3 and 6 months, and 1 year after surgery. Subjects will complete the same psychometric measures to identify differences in psychological and psychosocial responses to standard laparoscopic and percutaneous scars. Patients will also complete a measure on scar satisfaction. The investigators hope to identify any differences between standard laparoscopic versus percutaneous approaches.


Eligibility criteria: Inclusion Criteria:

* Body Mass Index 35 to 45
* Undergoing Bariatric Surgery

Exclusion Criteria:

* Body Mass Index \<35 or \>45
* Previous Bariatric Surgery

Primary outcomes:
measure: Change in Scar satisfaction
timeFrame: Baseline, 3 weeks, 3 months, 6 months and 1 year post-op
Secondary outcomes:
measure: Change in the Abdominal pain scale
timeFrame: Baseline, 1 day post-op, 3 weeks, 3 months, 6 months and 1 year post-op
Other outcomes:
measure: Change in Psychometric testing questionnaire
timeFrame: Baseline, 3 weeks, 3 months, 6 months and 1 year post-op
Locations:
city: Durham
country: United States
facility: Duke Center for Metabolic and Weight Loss Surgery
state: North Carolina
Study officials:
affiliation: Duke University
name: Dana Portenier, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06600360: Accuracy of Teledentistry for Diagnosis and Treatment Need in Dental Caries Detection Versus Clinical Examination on a Group of Egyptian Children: A Diagnostic Accuracy Study
Official title: Accuracy of Teledentistry for Diagnosis and Treatment Need in Dental Caries Detection Versus Clinical Examination on a Group of Egyptian Children: A Diagnostic Accuracy Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Teledentistry
Keywords: Teledentistry in diagnosis and treatment planning
Teledentistry
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 102
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants are Egyptian children with dental caries attending the diagnostic center at the Pediatric Dentistry and Dental Public Health Department, Faculty of Dentistry, Cairo University, Egypt.

Brief summary: The aim of this study is to assess the accuracy of teledentistry for diagnosis and treatment need in dental caries detection versus clinical examination on a group of Egyptian children.

Detailed description: The objective of this study is to assess the precision of using the mobile photographic method of teledentistry for dental caries diagnosis and treatment need of pediatric Egyptian children. This will be assessed by measuring the diagnostic accuracy of the mobile photographic method versus direct clinical oral examination for the same group of participants.

Eligibility criteria: Inclusion Criteria:

* Egyptian pediatric patients aged 4 to 12 years with a chief complaint of dental caries with or without pain.
* Both genders are included.

Exclusion Criteria:

* Egyptian pediatric patients with systemic conditions that will affect their treatment needs.
* Refusal of participation.
* Refusal to sign the informed consent.

Primary outcomes:
measure: Teledentistry for dental caries detection
timeFrame: 3 months
Secondary outcomes:
measure: Clinical dental caries examination
timeFrame: 3 months
measure: Reliability of treatment needs
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01552460: Brain Genomics Superstruct Project
Official title: Brain Genomics Superstruct Project
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autism Spectrum Disorders
Keywords: Autism Spectrum Disorders
Brain Imaging
Genetics
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Harvard University
First posted: 2012-03-13
Enrollment: 61
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with Autism Spectrum Disorders ages 13 and older.

Brief summary: The purpose of this study is to explore the effects of genes and genetic variation on brain structure and function. Investigators at Harvard plan to explore the relationship between candidate genes that affect cognitive performance and brain structure/function. Since brain phenotypes reflect more proximal sequelae of gene activity, neuroimaging measures may show greater sensitivity than cognitive performance to measure gene effects.


Eligibility criteria: Inclusion Criteria:

1. 13 years or older
2. Subject must have a current DSM-IV diagnosis of high functioning ASD, based on past evaluations at the Bressler Clinic.
3. Subjects must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
4. Each subject must understand the nature of the study. The subject must sign an IRB approved informed consent.

Exclusion Criteria:

1. IQ \< 70 bassed on evaluation in the Bressler Clinic.
2. Contraindication to MRI including presence of metal or surgical devices (plates, implants, braces or other items).
3. Neuropsychiatric conditions (such as dementia) which sufficiently impair cognition such that a surrogate consent would be required.
4. Neurological disorders associated with gross brain pathology (other than atrophy), e.g., stroke, tumors, or demyelinating diseases.
5. Pregnancy.

Primary outcomes:
measure: Neuroimaging phenotype
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Gagan Joshi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02271360: Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
Official title: Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Infertility
Keywords: infertility ICSI OHSS Calcium Dobesilate Cabergoline
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2014-10-22
Enrollment: 200
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare the effect of oral Calcium Dobesilate to oral Cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI).

Detailed description: Two hundred and twenty women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A, (Calcium Dobesilate group), 1 cap / 8 hs Doxium ( 500mg) will be given at day of HCG injection and for 21 days; while in group B (Cabergoline group), 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days.

Eligibility criteria: Patients enrolled in the study were infertile women undergoing ICSI with one of the following criteria: previous episodes of OHSS, polycystic ovaries (i.e., \> 24 antral follicles present on baseline ultrasound examination), high AMH (\> 3.0 ng/mL), large number of small follicles (8 to 12 mm) seen on ultrasound during ovarian stimulation, high s.E2 at hCG trigger (E2 \>3000 pg/ml or rapidly rising s.E2), presence of \> 20 follicles by ultrasound on day of retrieval or large number of oocytes retrieved (\> 20).

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of participants with ovarian hyperstimulation syndrome (OHSS)
timeFrame: weekly for eight weeks
Secondary outcomes:
measure: pregnancy rate
timeFrame: 14 days after embryos transfer
Other outcomes:
Locations:
city: Benha
country: Egypt
facility: Benha univesity hospital
state: El Qualyobia
Study officials:
affiliation: lecturer of ob/gyn
name: khalid mohamed, MD
role: STUDY_CHAIR
affiliation: lecturer of ob/gyn
name: ahmed saad, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02160860: Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
Official title: Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2014-06-11
Enrollment: 1997
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age 3\~18 children

Brief summary: Epidemiology of Helicobacter Pylori Infection Among Shanghai Children.

Detailed description: To get an understanding of the Hp infection general situation and provide evidence for Hp control, we are planning to run a free physical examination and lab test for a group of children. We are going to proceed with Hp-IgG test, 13C urea breath test and salivary Hp urea antigen test together to screening and diagnosing it.

Eligibility criteria: Inclusion Criteria:

* Age 3\~18
* Not been Clinical diagnosis of

Exclusion Criteria:

* Had antibiotics in the past week
* Had Bismuth or PPI

Primary outcomes:
measure: HP Infection Rate Estimation for Shanghai Children
timeFrame: Sampling complete before June 30, 2014. Lab test finish within 10 weeks. Report release within 3 weeks after all test finished.
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Pujiang Community Health Service Center
state: Shanghai
Study officials:
affiliation: Director of GI Department of Children's Hospital of Fudan University
name: HAUNG Ying, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00221260: Perioperative Epidural Trial (POET) Pilot Study
Official title: Perioperative Epidural Trial (POET) Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post Operative Pain Control
Keywords: Analgesia
anesthesia
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2005-09-22
Enrollment: 250
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate if the use of perioperative neuraxial blockade reduces post-operative mortality and cardiorespiratory events compared to intraoperative general anesthesia AND postoperative IV narcotic analgesia. This is a feasibility study to determine if recruitment and execution of the protocol could be done in a timely manner in a much larger trial


Eligibility criteria: Inclusion Criteria:

Subjects at high risk of cardio-respiratory complications post operatively.

Exclusion Criteria:

Contraindication to epidural anesthesia

Primary outcomes:
measure: Combined mortality, MI, cardiac arrest, post operative pneumonia , and respiratory failure
Secondary outcomes:
measure: DVT, pulmonary embolism, TIA, CVA, CHF, clinically significant bradycardia/hypotension
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Vancouver General Hospital, Clinical Health Research Unit
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Peter Choi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Choi PT, Beattie WS, Bryson GL, Paul JE, Yang H. Effects of neuraxial blockade may be difficult to study using large randomized controlled trials: the PeriOperative Epidural Trial (POET) Pilot Study. PLoS One. 2009;4(2):e4644. doi: 10.1371/journal.pone.0004644. Epub 2009 Feb 27.
Clinical trial NCT04260360: Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
Official title: Phase 1 Trial Evaluating the Safety and Tolerability of NanoDoce® Intratumoral Injection in Subjects With Localized Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Renal Cell Carcinoma
Kidney Cancer
Adenocarcinoma of Kidney
Adenocarcinoma, Renal
Renal Cell Cancer
Keywords: docetaxel
Lead sponsor: NanOlogy, LLC
Sponsor class: INDUSTRY
Collaborators: name: US Biotest, Inc.
First posted: 2020-02-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.

Detailed description: NanoDoce is very small (submicron) particles of the chemotherapy drug, docetaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at the site of disease with less systemic exposure than intravenously administered chemotherapy. In this study, the submicron particle docetaxel will be injected directly into tumors in the kidney of people with renal cell carcinoma that is localized to (has not spread beyond) the kidney. All subjects in this study will receive NanoDoce and will be evaluated to see if NanoDoce is safe.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent;
* Age ≥18 years;
* Localized T1a renal cell carcinoma;
* Maximum tumor volume of 25.0 mL;
* Performance Status (ECOG) 0-2;
* Life expectancy of at least 6 months;
* Adequate marrow, liver, and renal function;

  * ANC ≥ 1.5 x 109/L
  * Hemoglobin ≥ 9.5 grams/dL
  * Platelets ≥ 75 x 109/L
  * Total bilirubin ≤ 1.5x institutional ULN
  * AST/ ALT ≤ 2.5x institutional ULN
  * Creatinine ≤ 1.5x institutional ULN
  * eGFR \< 60 mL/min/1.73m2
* Adequate method of birth control.

Exclusion Criteria:

* Renal cyst;
* Multifocal or bilateral renal mass;
* Known hypersensitivity to any of the study drug or reconstitution components;
* Pregnant or breastfeeding female;
* Administration of an investigational product in a clinical trial within 3 months prior to consent;
* Investigator's opinion of subject's probable noncompliance or inability to understand the trial and/or give adequate informed consent;
* Known drug or alcohol abuse.

Primary outcomes:
measure: Number of participants with treatment emergent adverse events
timeFrame: Day 1 to 180 days post-last NanoDoce injection
Secondary outcomes:
measure: Concentration of docetaxel in the systemic circulation post-injection
timeFrame: Screening, Day 1, Day 2, Day 15, Day 27, Day 30, Day 31, Day 45, Month 2, Month 3, Month 4, Month 5, and 180 days post-last NanoDoce injection
Other outcomes:
Locations:
Study officials:
affiliation: US Biotest, Inc.
name: Rose Marie Cavanna-Mast, RT, CCRA
role: STUDY_DIRECTOR
References:
Clinical trial NCT06900660: Evaluation of the Skin-Beautifying Effects of Collagen Drinks
Official title: Evaluation of the Skin-Beautifying Effects of Collagen Drinks
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Skin Aging
Lead sponsor: Simply Plus Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Chia Nan University of Pharmacy ＆ Science
First posted: 2025-03-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims to investigate the skin beauty benefits of collagen drinks in healthy individuals.


Eligibility criteria: Inclusion Criteria:

1. Age over 18 years
2. Healthy people

Exclusion Criteria:

1. Non-volunteer
2. Pregnant and lactating women
3. Hypersensitivity to the assigned product
4. Diagnosed with skin diseases, liver diseases, kinedy disease, and other severe diseases
5. Cosmetic, drug, or food allergies
6. Concurrent aesthetic treatments (e.g., intense pulse light, medical peelings, or laser therapy)
7. Aceepted aesthetic treatments one month ago before the study
8. Chronic sun exposure (over 3 hours/day)
9. The members of the research team

Primary outcomes:
measure: Measurement of skin hydration
timeFrame: Week 0, 4, 8
measure: Measurement of skin elasticity
timeFrame: Week 0, 4, 8
measure: Measurement of skin wrinkles
timeFrame: Week 0, 4, 8
measure: Measurement of skin pores
timeFrame: Week 0, 4, 8
measure: Measurement of collagen content
timeFrame: Week 0, 4, 8
measure: Measurement of wrinkles around the eyes
timeFrame: Week 0, 4, 8
measure: Measurement of skin brightness
timeFrame: Week 0, 4, 8
measure: Measurement of collagen levels in the blood
timeFrame: Week 0, 8
measure: Measurement of hyaluronic acid levels in the blood
timeFrame: Week 0, 8
measure: Measurement of superoxide dismutase (SOD) levels in the blood
timeFrame: Week 0, 8
Secondary outcomes:
measure: The change of self-assessment skin condition
timeFrame: Week 0, 4, 8
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Chia Nan University of Pharmacy ＆ Science
Study officials:
affiliation: Department of Cosmetic Science, Chia Nan University of Pharmacy ＆ Science
name: Chia-Hua Liang
role: PRINCIPAL_INVESTIGATOR
References: